|
1,147
|
| 7485 |
Obesity
|
|
increases_quantity of
|
CRP
|
|
| 7486 |
inflammatory response
|
|
increases_quantity of
|
CRP
|
|
|
10591334
|
Diabetes mellitus, type II
Obesity
Insulin resistance
|
|
1,279
|
| 8733 |
Sasapyrine
|
|
decreases_quantity of
|
CRP
|
|
|
17959861
|
Diabetes mellitus, type II
Insulin resistance
|
|
1,409
|
| 10030 |
Anakinra
|
|
decreases_quantity of
|
CRP
|
|
|
17429083
|
Diabetes mellitus, type II
Insulin resistance
|
|
1,573
|
| 11269 |
Fenofibrate
|
|
decreases_quantity of
|
CRP
|
|
|
19023279
|
Diabetes mellitus, type II
Insulin resistance
Metabolic syndrome
|
|
1,945
|
| 15019 |
sex
|
|
affects_quantity of
|
CRP
|
in patients with metabolic syndrome
|
|
19707530
|
Diabetes mellitus, type II
Insulin resistance
Metabolic syndrome
|
|
2,036
|
| 16178 |
REN
|
|
increases_expression of
|
CRP
|
in aorta; in Ren-2 rats
|
| 16184 |
Valsartan
|
|
decreases_expression of
|
CRP
|
in aorta; in Ren-2 rats
|
| 16190 |
Tempol
|
|
decreases_expression of
|
CRP
|
in aorta; in Ren-2 rats
|
|
17533199
|
Diabetes mellitus, type II
Insulin resistance
|
|
2,104
|
| 17736 |
Major depressive disorder
|
|
increases_quantity of
|
CRP
|
|
|
20161799
|
Major depressive disorder
|
|
2,114
|
| 17269 |
CRP
|
|
affects_activity of
|
atherosclerotic lesions
|
|
|
19475771
|
Diabetes mellitus, type II
Insulin resistance
|
|
2,218
|
| 18697 |
Hydrochlorothiazide
|
|
increases_quantity of
|
CRP
|
in blood
|
| 18698 |
Candesartan
|
NOT |
affects_quantity of
|
CRP
|
in blood
|
|
18981327
|
Diabetes mellitus, type II
Obesity
Insulin resistance
|
|
2,271
|
| 19395 |
Major depressive disorder
|
|
increases_quantity of
|
CRP
|
|
|
21756997
|
Major depressive disorder
|
|
2,664
|
| 25084 |
GCKR rs1260326
|
|
affects_quantity of
|
CRP
|
|
|
21674002
|
Diabetes mellitus, type II
Insulin resistance
Metabolic syndrome
|
|
3,293
|
| 30271 |
total sleep deprivation (TSD)
|
|
decreases_quantity of
|
CRP
|
|
|
17524614
|
Diabetes mellitus, type II
Insulin resistance
|
|
3,447
|
| 32206 |
carnitine supplementation
|
|
decreases_quantity of
|
CRP
|
|
|
20068559
|
Diabetes mellitus, type II
Insulin resistance
Fatty liver disease, nonalcoholic
|
|
3,512
|
| 32663 |
Obesity
|
|
increases_quantity of
|
CRP
|
in blood serum
|
|
19356713
|
Diabetes mellitus, type II
Obesity
Insulin resistance
|
|
3,564
|
| 33244 |
impaired glucose tolerance
|
|
increases_quantity of
|
CRP
|
in blood plasma
|
|
20676218
|
Diabetes mellitus, type II
Insulin resistance
|
|
4,666
|
| 46429 |
Coronary heart disease
|
|
increases_quantity of
|
CRP
|
|
|
23150690
|
Cardiovascular disease
Coronary heart disease
|
|
4,717
|
| 46736 |
Cardiovascular disease
|
|
increases_quantity of
|
CRP
|
|
| 46743 |
CRP
|
|
increases_expression of
|
AGER
|
|
| 46746 |
CRP
|
|
decreases_expression of
|
NOS3
|
by increasing the expression of RAGE
|
| 46747 |
CRP
|
|
decreases_quantity of
|
NOS3
|
by increasing the expression of RAGE
|
| 46748 |
CRP
|
|
decreases_activity of
|
cell migration
|
|
| 46749 |
CRP
|
|
decreases_activity of
|
cell adhesion
|
|
| 46750 |
CRP
|
|
decreases_activity of
|
cell population proliferation
|
|
| 46751 |
CRP
|
|
increases_activity of
|
apoptotic process
|
|
| 46753 |
CRP
|
|
increases_quantity of
|
Reactive oxygen species
|
in endothelial cells
|
|
22301267
|
Cardiovascular disease
|
|
5,801
|
| 54735 |
HNF1A
|
|
affects_expression of
|
CRP
|
in INS-1 cells
|
|
23803251
|
Diabetes mellitus, type II
Insulin resistance
|
|
6,597
|
| 63285 |
Metformin
|
|
decreases_quantity of
|
CRP
|
|
| 63286 |
exercise
|
|
decreases_quantity of
|
CRP
|
|
|
23505172
|
Diabetes mellitus, type II
Insulin resistance
|
|
6,803
|
| 66042 |
Stroke, ischemic
|
|
increases_quantity of
|
CRP
|
in blood serum; in acute ischemic stroke
|
|
25807139
|
Stroke, ischemic
|
|
6,896
|
| 67509 |
Conjugated linoleic acid
|
|
increases_quantity of
|
CRP
|
in blood serum
|
|
19954947
|
Diabetes mellitus, type II
Insulin resistance
|
|
7,450
|
| 73307 |
conjugated linoleic acid supplementation
|
NOT |
affects_quantity of
|
CRP
|
|
|
27834186
|
Atherosclerosis
|
|
7,468
|
| 73765 |
conjugated linoleic acid 50:50 blend supplementation
|
NOT |
affects_quantity of
|
CRP
|
|
|
15447895
|
Diabetes mellitus, type II
Insulin resistance
|
|
7,520
|
| 74172 |
CRP
|
|
increases_activity of
|
Cardiovascular disease
|
|
| 74243 |
CRP
|
|
increases_activity of
|
Coronary heart disease
|
|
| 74244 |
CRP
|
|
increases_activity of
|
Cancer
|
|
|
18156284
|
Diabetes mellitus, type II
Cancer
Insulin resistance
Cardiovascular disease
Coronary heart disease
|
|
7,534
|
| 74394 |
macrophage
|
|
increases_expression of
|
CRP
|
|
| 74396 |
aortic smooth muscle cell
|
|
increases_expression of
|
CRP
|
|
| 74398 |
CRP
|
|
increases_activity of
|
innate immune response
|
|
| 74399 |
CRP
|
|
increases_activity of
|
FCGR
|
|
| 74401 |
CRP
|
|
interacts (colocalizes) with
|
OxLDL
|
|
|
23114023
|
Immunological
Cardiovascular disease
Atherosclerosis
|
|
7,535
|
| 74406 |
CRP
|
|
interacts (colocalizes) with
|
Lysophosphatidylcholine
|
in 293FT cells
|
| 74436 |
CRP
|
|
decreases_activity of
|
OxLDL import
|
in macrophages
|
| 74441 |
CRP
|
|
decreases_activity of
|
foam cell differentiation
|
|
| 74445 |
CRP
|
|
decreases_activity of
|
Lysophosphatidylcholine
|
in 293FT cells
|
|
23114023
|
Cardiovascular disease
Atherosclerosis
|
|
7,711
|
| 77125 |
Gestational diabetes mellitus
|
|
increases_quantity of
|
CRP
|
in blood plasma
|
|
20960114
|
Gestational diabetes mellitus
|
|
7,785
|
| 77756 |
acute-phase response
|
|
increases_expression of
|
CRP
|
in hepatocyte
|
|
11556518
|
Inflammation
|
|
7,795
|
| 77762 |
CRP
|
|
affects_activity of
|
abnormal carotid artery compliance
|
in males, in subjects with CRP -717A>G, -286C >T>A, +1059G>C, +1444C>T and +1846G>A haplotype, in combination with CFH Tyr402His polymorphism
|
| 78038 |
CRP
|
|
affects_activity of
|
Atherosclerosis
|
in males, in subjects with CRP -717A>G, -286C >T>A, +1059G>C, +1444C>T and +1846G>A haplotype, in combination with CFH Tyr402His polymorphism
|
| 78041 |
CRP
|
NOT |
affects_activity of
|
abnormal carotid artery compliance
|
in females, in subjects with CRP -717A>G, -286C >T>A, +1059G>C, +1444C>T and +1846G>A haplotype, in combination with CFH Tyr402His polymorphism
|
|
19076828
|
Cardiovascular disease
Atherosclerosis
|
|
7,879
|
| 78560 |
CRP
|
|
increases_activity of
|
complement activation, classical pathway
|
|
| 78561 |
atherosclerotic lesions
|
|
increases_expression of
|
CRP
|
|
| 78562 |
CRP
|
|
interacts (colocalizes) with
|
Terminal complement C5b-9 complex
|
|
|
26091721
|
Immunological
Atherosclerosis
|
CIDeRplus